Blueprint Medicines (BPMC)
(Delayed Data from NSDQ)
$91.44 USD
+0.59 (0.65%)
Updated Aug 8, 2024 04:00 PM ET
After-Market: $91.66 +0.22 (0.24%) 7:58 PM ET
2-Buy of 5 2
F Value D Growth A Momentum D VGM
Brokerage Reports
Blueprint Medicines Corporation [BPMC]
Reports for Purchase
Showing records 341 - 360 ( 520 total )
Company: Blueprint Medicines Corporation
Industry: Medical - Biomedical and Genetics
HEALTHCARE - The Week Ahead in Life Sciences
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Blueprint Medicines Corporation
Industry: Medical - Biomedical and Genetics
Biotechnology- From Underneath the Rubble Sing a Rebel Song
Provider: WEDBUSH SECURITIES INC.
Analyst: Research Department
Company: Blueprint Medicines Corporation
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Blueprint Medicines Corporation
Industry: Medical - Biomedical and Genetics
Company: Blueprint Medicines Corporation
Industry: Medical - Biomedical and Genetics
Company: Blueprint Medicines Corporation
Industry: Medical - Biomedical and Genetics
Company: Blueprint Medicines Corporation
Industry: Medical - Biomedical and Genetics
Company: Blueprint Medicines Corporation
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Blueprint Medicines Corporation
Industry: Medical - Biomedical and Genetics
Imagine There?s No Road Show; Notes from BPMC
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Blueprint Medicines Corporation
Industry: Medical - Biomedical and Genetics
Imagine There?s No Road Show; Notes from BPMC
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Blueprint Medicines Corporation
Industry: Medical - Biomedical and Genetics
Company: Blueprint Medicines Corporation
Industry: Medical - Biomedical and Genetics
Strong PIONEER Data Paves Way for Registration Study
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Blueprint Medicines Corporation
Industry: Medical - Biomedical and Genetics
Best Case Scenario - Right Dose, Right Results
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Blueprint Medicines Corporation
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Blueprint Medicines Corporation
Industry: Medical - Biomedical and Genetics
Thoughts Ahead of PIONEER Data Update Next Month; Reit Buy and $100 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Blueprint Medicines Corporation
Industry: Medical - Biomedical and Genetics
Company: Blueprint Medicines Corporation
Industry: Medical - Biomedical and Genetics
Company: Blueprint Medicines Corporation
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department